Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
about
The structural basis of XRCC1-mediated DNA repairATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersPrognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapyFOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsAtaxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.Synergistic cytotoxicity and DNA strand breaks in cells and plasmid DNA exposed to uranyl acetate and ultraviolet radiation.Exploiting base excision repair to improve therapeutic approaches for pancreatic cancerJWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapyLoss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma.Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics studyPredictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.High mobility group protein B1 is a predictor of poor survival in ovarian cancer.The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).DNA damage repair in ovarian cancer: unlocking the heterogeneity.
P2860
Q28259282-C5C5FCD8-375E-4373-9E01-9CCDE348AF11Q28271111-147F77E5-3B0D-413D-8882-0DE42A3A278AQ33598872-9342A78E-8D1F-4EB6-B9A3-3EC5F92F4C29Q33651605-2FFA36B2-4CCD-4095-9F8E-209FF3967F8FQ34603025-42982B0B-4080-4BC8-915A-0C105F848B6AQ35246419-48990127-085D-469C-A6F2-7F9D25FEE6B9Q35395549-FB1E64D1-B27B-44F8-A692-C17D85A85032Q35596340-583F1F53-61AE-4395-9663-36C2141311E8Q35596477-5C65BABE-A8BF-4BE3-ADE9-67D453FEA5A4Q36291991-39A82BCF-F739-4F58-A6A4-5748623708D1Q38958030-63174A75-977F-49A7-8DC8-EDDEB0F3452BQ39035676-80A882C1-950D-48C3-A563-320AEBC27EA5Q39598112-BD9E5985-E655-486F-9E0C-4ADD832A7725Q40979612-44B87D97-7AD3-4DB4-914F-03F6683733A2Q47152534-D80EF2DB-98C5-4E52-B039-76A4FED63BA4Q54974198-68235AB1-6BA6-4168-8826-FB2855FC92F8Q55399645-7587D332-5BA7-41C1-A778-563850FCA05A
P2860
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@en
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@nl
type
label
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@en
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@nl
prefLabel
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@en
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@nl
P2093
P2860
P356
P1476
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
@en
P2093
Claire Hawkes
Rachel Abbotts
Rebeka Sultana
Stephen Chan
Tarek Abdel-Fatah
P2860
P304
P356
10.1002/IJC.27980
P577
2012-12-27T00:00:00Z